Literature DB >> 1924047

Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?

M J Abramson1, A J Barnett, G O Littlejohn, M M Smith, S Hall.   

Abstract

To document the prevalence and progression of pulmonary involvement in scleroderma (systemic sclerosis including the CREST syndrome), the clinical notes and lung function records of 113 cases were reviewed. Lung function was normal in 39 cases, isolated impairment of DLCO was found in 38 patients, a restrictive defect was present in 27 cases and there was evidence of airflow obstruction in 9 cases. The median duration of symptoms was 10 years. Dyspnoea and an interstitial pattern on chest X-ray were associated with impaired lung function. Death during the period of review was significantly related to initial impairment of the DLCO. Sixty-six patients (53 women and 13 men) underwent repeat spirometry at least 1 year after initial testing. The rates of change in VC and FEV1 were no more rapid than would be expected for normal subjects. There was no significant difference in rates of change between men and women or between dyspnoeic patients and those who were asymptomatic. The extent of skin involvement and the presence of interstitial fibrosis on chest X-ray were unrelated to the rate of loss of lung function. It is concluded that most scleroderma patients in this study had abnormal lung function when first tested, but overall significant worsening of spirometry was not found.

Entities:  

Mesh:

Year:  1991        PMID: 1924047      PMCID: PMC2399092          DOI: 10.1136/pgmj.67.789.632

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  18 in total

1.  Longitudinal changes in forced expiratory volume in one second in adults. Methodologic considerations and findings in healthy nonsmokers.

Authors:  B Burrows; M D Lebowitz; A E Camilli; R J Knudson
Journal:  Am Rev Respir Dis       Date:  1986-06

Review 2.  Cardiopulmonary manifestations of systemic sclerosis.

Authors:  G R Owens; W P Follansbee
Journal:  Chest       Date:  1987-01       Impact factor: 9.410

3.  Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis.

Authors:  M Peters-Golden; R A Wise; P Schneider; M Hochberg; M B Stevens; F Wigley
Journal:  Medicine (Baltimore)       Date:  1984-07       Impact factor: 1.889

4.  The effect of D-penicillamine on pulmonary findings in systemic sclerosis.

Authors:  V D Steen; G R Owens; C Redmond; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1985-08

5.  Serial pulmonary function in systemic sclerosis.

Authors:  P D Schneider; R A Wise; M C Hochberg; F M Wigley
Journal:  Am J Med       Date:  1982-09       Impact factor: 4.965

6.  Pulmonary involvement in systemic sclerosis (scleroderma).

Authors:  V D Steen; G R Owens; G J Fino; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1985-07

7.  Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.

Authors:  R G Ungerer; D P Tashkin; D Furst; P J Clements; H Gong; M Bein; J W Smith; N Roberts; W Cabeen
Journal:  Am J Med       Date:  1983-07       Impact factor: 4.965

8.  Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis.

Authors:  M Peters-Golden; R A Wise; M C Hochberg; M B Stevens; F M Wigley
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

9.  The clinical significance of the anticentromere antibody.

Authors:  M H Miller; G O Littlejohn; A Davidson; B Jones; D J Topliss
Journal:  Br J Rheumatol       Date:  1987-02

10.  Progressive systemic sclerosis in Auckland: a ten year review with emphasis on prognostic features.

Authors:  R J Eason; P L Tan; P J Gow
Journal:  Aust N Z J Med       Date:  1981-12
View more
  6 in total

1.  Changes in pulmonary function in systemic sclerosis.

Authors:  L Czirják; E Szolnoki; Z Nagy; G Szegedi
Journal:  Postgrad Med J       Date:  1992-05       Impact factor: 2.401

2.  A longitudinal study of pulmonary function in Danish patients with systemic sclerosis.

Authors:  S Jacobsen; P Halberg; S Ullman; M Høier-Madsen; J Petersen; J Mortensen; A Wiik
Journal:  Clin Rheumatol       Date:  1997-06       Impact factor: 2.980

3.  Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort.

Authors:  Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes
Journal:  Arthritis Res Ther       Date:  2010-09-02       Impact factor: 5.156

4.  Deterioration of lung function is associated with presence of IgM rheumatoid factor and smoking in patients with systemic sclerosis.

Authors:  Berit Broholm; Susanne Ullman; Poul Halberg; Søren Jacobsen
Journal:  Clin Rheumatol       Date:  2008-06-05       Impact factor: 2.980

5.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

6.  Value of lung diffusing capacity for nitric oxide in systemic sclerosis.

Authors:  Giovanni Barisione; Alessandro Garlaschi; Mariaelena Occhipinti; Michele Baroffio; Massimo Pistolesi; Vito Brusasco
Journal:  Physiol Rep       Date:  2019-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.